Allergy clinical trial services market seen reaching $1.65 billion by 2030

By AI, Created 5:08 PM UTC, May 18, 2026, /AGP/ – The allergy clinical trial services market is forecast to expand through 2030 as allergic diseases rise globally and sponsors lean more on specialized research, lab testing and decentralized trial models. North America leads today, while Asia-Pacific is expected to grow fastest.

Why it matters: - Allergy-related conditions are pushing more demand for clinical trial services that can test new treatments for asthma, rhinitis, food allergies and drug allergies. - The market is tied to broader growth in clinical research spending, regulatory requirements and the move toward more precise, data-driven trial designs. - The 2024 National Health Interview Survey found about 29.5% of US children were diagnosed with a seasonal allergy, eczema or food allergy, up from 20.6% in the prior survey year.

What happened: - The Business Research Company projected the allergy clinical trial services market will reach $1.66 billion by 2030. - The market is forecast to rise from $1.15 billion in 2025 to $1.24 billion in 2026, a 7.3% compound annual growth rate. - The outlook was published in London on May 13, 2026. - The report describes allergy clinical trial services as specialized research programs that assess safety, efficacy and dosing for allergy therapies.

The details: - The study includes trials for asthma, rhinitis, food allergies and drug allergies. - The services rely on structured protocols, close patient monitoring and detailed data collection to support regulatory approval and clinical use. - Growth drivers cited in the report include rising allergic disease incidence, higher clinical research investment, stricter study protocols, stronger laboratory testing and expansion in pharmaceutical and biotechnology activity. - Future growth is expected to be supported by precision medicine, AI-powered analytics, remote monitoring, decentralized trial models, phase II and III allergy studies, regulatory compliance and efficient data management. - The report highlights remote monitoring, patient recruitment and retention, electronic data capture systems, bioanalytical and lab testing services, medical writing and regulatory affairs support as key trends. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period. - Other regions covered include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample is available here: Download a free sample - The full report is available here: View the full report

Between the lines: - The forecast suggests allergy research is moving from a niche clinical category to a more important part of the broader drug development pipeline. - Faster growth in Asia-Pacific points to a shift in where trial activity and research infrastructure may expand next. - The emphasis on decentralized trials and electronic data capture signals a market where operational efficiency matters as much as scientific progress.

What’s next: - The market is expected to keep expanding as allergic disease rates stay elevated and sponsors increase investment in phase II and III studies. - More trial programs are likely to add remote monitoring, patient-retention tools and regulatory support functions. - Clinical research providers will likely compete more on data quality, speed and compliance as allergy studies become more technologically advanced.

The bottom line: - Allergy clinical trial services are on track for steady growth through 2030, with rising allergy prevalence and more sophisticated trial methods driving demand.